Clinical Trial Update: A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study assessing subcutaneous efgartigimod with PH20 for Bullous Pemphigoid has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Efgartigimod PH20 SC (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Bullous Pemphigoid | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-10-23